- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03733990
A Study to Evaluate Safety, Tolerability and Preliminary Efficacy of FP-1305 in Cancer Patients (MATINS)
A Phase I/II Open-Label, Three-Part, Dose-Finding and Separate Cohort Expansion Trial to Assess the Safety, Tolerability and Preliminary Efficacy of Repeated Doses of CLEVER-1 Antibody FP-1305, in Subjects With Advanced Solid Tumours
This is a first in human study to identify whether FP-1305 is suitable to use in humans. The previous pre-clinical studies have demonstrated that FP-1305 binds to a receptor known as CLEVER-1. CLEVER-1 has been shown to support tumour growth. No significant adverse events were witnessed in primates and the dose used will be 300 fold lower than the dose provided to primates which showed no toxicity.
The patients with advanced melanoma, uveal melanoma, cholangiocarcinoma, gallbladder cancer, ER+ breast, gastric, ovarian, pancreatic, colorectal, liver or anaplastic thyroid cancer who have exhausted all licenced therapeutic options will die due to their disease. Based on the investigator's existing data CLEVER-1 is expressed in these tumour types. Inhibition of CLEVER-1 with FP-1305 may have an anti-tumour effect in these patients.
Study Overview
Study Type
Enrollment (Actual)
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Contact
- Name: Marie-Louise Fjällskog, MD, PhD, Assoc Prof
- Phone Number: 358 02 469 5151
- Email: marie-louise.fjaellskog@faron.com
Study Contact Backup
- Name: Maria Oliveira
- Phone Number: 358 02 469 5151
- Email: maria.oliveira@faron.com
Study Locations
-
-
-
Helsinki, Finland, 00290
- Clinical Research Institute HUCH Ltd
-
Oulu, Finland, 90220
- Oulu University Hospital
-
Tampere, Finland, 33520
- Tampere University Hospital
-
Turku, Finland, 20520
- Turku University Hospital
-
-
-
-
-
Villejuif, France, 94805
- The Institut Gustave Roussy
-
-
-
-
-
Rotterdam, Netherlands, 3015 GD
- Erasmus University Medical Center Rotterdam
-
-
-
-
-
Madrid, Spain, 28050
- START Madrid - CIOCC Hospital HM Sanchinarro
-
-
-
-
-
Birmingham, United Kingdom, B15 2GW
- Queen Elizabeth Hospital Birmingham
-
Manchester, United Kingdom, M20 4BX
- The Christie Nhs Foundation Trust
-
-
Surrey
-
Sutton, Surrey, United Kingdom, SM2 5PT
- The Royal Marsden NHS Foundation Trust
-
-
-
-
Texas
-
San Antonio, Texas, United States, 78229-3901
- The University of Texas Health Science Center at San Antonio
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Subjects must meet all of the following inclusion criteria to be eligible for participation in the clinical trial:
- Written Informed Consent
- Aged ≥ 18 years male or female
- Tumour sample should be collected during screening period. If a recent tumour biopsy obtained within six months before the date of consent is available (or older, as agreed on a case by case basis with the sponsor), that may be used. At the discretion of the sponsor, the tumour sample may be optional for certain subjects in Part III
- Life expectancy > 12 weeks
Histologically confirmed advanced (inoperable or metastatic) malignancies without standard therapeutic options available:
- Hepatocellular carcinoma
- Gallbladder cancer or intra- or extrahepatic cholangiocarcinoma
- Colorectal adenocarcinoma
- Serous poorly differentiated (Grade 3) ovarian adenocarcinoma or undifferentiated ovarian cancer
- Pancreatic ductal adenocarcinoma
- Immunotherapy (IO) refractory cutaneous melanoma (progression either on or after programmed cell death protein-1 (PD-1)/programmed cell death ligand-1 (PD-L1) or cytotoxic T-lymphocyte antigen-4 (CTLA-4) antibody therapy)
- Uveal melanoma in Parts II and III
- Gastric adenocarcinoma (including adenocarcinoma of the distal esophagus / GE junction) in Parts II and III
- ER+ breast cancer in Parts II and III
- Anaplastic thyroid cancer in Parts II and III
- ECOG performance status 0 or 1
- Measurable disease in Parts II and III
- Adequate bone marrow, liver and kidney function defined as Blood white blood cell ≥ lower limit of normal Blood neutrophil count ≥ 1x10(9)/L Blood platelet count ≥ 100x10(9)/L, for HCC ≥ 50x10(9)/L Blood haemoglobin ≥ 9.0 g/dL Creatinine clearance > 40 mL/min calculated by Cockcroft-Gault formula AST ≤ 3 X ULN (≤ 5 x ULN when HCC or hepatic metastases are present) ALT ≤ 3 X ULN (≤ 5 x ULN when HCC or hepatic metastases present) Bilirubin ≤ 1.5 X ULN Albumin ≥ 3.0 g/dL The most recent measurements taken during the screening period must be within the required limits for the patient to be considered eligible (i.e. criteria met once during the screening period are not sufficient if there are more recent measurements available that are not within the required limits. It is however acceptable to repeat measurements if the initial measurements or subsequent measurements taken during the screening period are not within the required limits; the patient is eligible providing that the newest measurements are within the required limits). However, once a subject is out of the screening period, and has had eligibility confirmed and been enrolled, the pre-dose laboratory assessments are not subjected to inclusion criteria limits, but only for investigators assessment of subject safety.
- Women of child-bearing potential must have a negative pregnancy test in serum prior to trial entry
- Women of child-bearing potential and men who have partners of child-bearing potential must be willing to practise highly effective contraception for the duration of the trial and for three months after the completion of treatment
Exclusion Criteria;
- Less than 21 days since the last dose of intravenous anticancer chemotherapy or less than five half-lives from a small molecule targeted therapy or oral anticancer chemotherapy before the first IMP administration
- Any immunotherapy within preceding 6 weeks from the first IMP administration
- Investigational therapy or major surgery within 4 weeks from the date of consent
- Active clinically serious infection > Grade 2 NCI-CTCAE version 5.0 (Appendix 5 - Common Toxicity Criteria Gradings) within preceding 2 weeks from the date of consent
- Brain metastases
- Subject has not recovered from the previous therapies to Grade ≤ 1 severity as classified by the NCI-CTCAE version 5.0 (except Grade ≤ 2 alopecia, neuropathy or thyroid disorders)
- Pregnant or lactating women
- History of second malignancy except for non-melanotic skin cancer, cervical carcinoma in situ or superficial bladder cancer, or any other malignancy treated previously with curative intent and more than three years without relapse
- Evidence of severe or uncontrolled systemic diseases, congestive cardiac failure New York Heart Association (NYHA) class 2 (Appendix 7 - NYHA classification), Myocardial Infarction (MI) within 6 months or laboratory finding that in the view of the investigator makes it undesirable for the subject to participate in the trial
- Any medical condition that the Investigator considers significant to compromise the safety of the subject or that impairs the interpretation of IMP toxicity assessment
- Confirmed human immunodeficiency virus infection
- Symptomatic cytomegalovirus infection
- Subjects with active auto-immune disorder (except type I diabetes, celiac disease, hypothyroidism requiring only hormone replacement, vitiligo, psoriasis, or alopecia)
- The subject requires systemic corticosteroid or other immunosuppressive treatment
- Subjects with organ transplants
- Subjects in dialysis
- Use of Live (attenuated) vaccines for 30 days prior to the start of study treatment, during treatment, and until last visit
- Subject is unwilling or unable to comply with treatment and trial instructions
- Subjects with known hypersensitivity to the IMP or any of the pharmaceutical ingredients
Specific Additional Exclusion Criteria for Hepatobiliary Cancers
- Any ablative therapy (Radio Frequency Ablation or Percutaneous Ethanol Injection) for HCC (this should not exclude subjects if target lesion(s) have not been treated and occurred > 6 weeks prior trial entry)
- Hepatic encephalopathy
- Ascites refractory to diuretic therapy
- Child-Pugh score ≥ 7
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Sequential Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: FP-1305 (bexmarilimab) 0.3 mg/kg
Part I, Dose-escalation FP-1305 0.3 mg/kg is administered in Q3W intervals
|
The study will test for the first time in patients with cancer, an experimental medicine, called FP-1305.
The study goal is to find the dose of FP-1305 that works best against cancer while it remains safe for use, tolerable and effective in patients with cancer.
Other Names:
|
Experimental: FP-1305 (bexmarilimab) 1 mg/kg
Part I and II, Dose-escalation FP-1305 1 mg/kg is administered in Q3W, Q2W or Q1W intervals
|
The study will test for the first time in patients with cancer, an experimental medicine, called FP-1305.
The study goal is to find the dose of FP-1305 that works best against cancer while it remains safe for use, tolerable and effective in patients with cancer.
Other Names:
|
Experimental: FP-1305 (bexmarilimab) 3 mg/kg
Part I and II, Dose-escalation FP-1305 3 mg/kg is administered in Q3W, Q2W or Q1W intervals
|
The study will test for the first time in patients with cancer, an experimental medicine, called FP-1305.
The study goal is to find the dose of FP-1305 that works best against cancer while it remains safe for use, tolerable and effective in patients with cancer.
Other Names:
|
Experimental: FP-1305 (bexmarilimab) 10 mg/kg
Part I and II, Dose-escalation FP-1305 10 mg/kg is administered in Q3W, Q2W or Q1W intervals
|
The study will test for the first time in patients with cancer, an experimental medicine, called FP-1305.
The study goal is to find the dose of FP-1305 that works best against cancer while it remains safe for use, tolerable and effective in patients with cancer.
Other Names:
|
Experimental: FP-1305 (bexmarilimab) 0.1 mg/kg
Part I Dose-escalation FP-1305 0.1 mg/kg is administered in three-week intervals
|
The study will test for the first time in patients with cancer, an experimental medicine, called FP-1305.
The study goal is to find the dose of FP-1305 that works best against cancer while it remains safe for use, tolerable and effective in patients with cancer.
Other Names:
|
Experimental: FP-1305 (bexmarilimab) 30 mg/kg
Part II Dose-escalation FP-1305 30 mg/kg is administered in Q3W, Q2W or Q1W intervals
|
The study will test for the first time in patients with cancer, an experimental medicine, called FP-1305.
The study goal is to find the dose of FP-1305 that works best against cancer while it remains safe for use, tolerable and effective in patients with cancer.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Dose limiting toxicities (DLT) in the trial subjects.
Time Frame: Up to one year
|
Tolerable dose(s) will be determined by the TITE-CRM based on the occurrence/non-occurrence of dose limiting toxicities in the trial subjects.
|
Up to one year
|
Incidence of Treatment Emergent Adverse Events (Safety and Tolerability)
Time Frame: Up to six years
|
Number of adverse events and serious adverse events.
Adverse events are collected, graded and reported according to the National Cancer Institute-Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 5.0.
|
Up to six years
|
The response (ORR, CBR and irORR) to the treatment.
Time Frame: Up to six years
|
The objective response rate (ORR), clinical benefit rate (CBR) and immune-related ORR (irORR) to the treatment will be determined by tumour imaging (tumor size) according to RECIST v.1.1.
Results from each tumour type, dose level and dosing frequency will be reported separately.
|
Up to six years
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Petri Bono, MD, PhD, Terveystalo Ltd
Publications and helpful links
General Publications
- Hollmen M, Maksimow M, Rannikko JH, Karvonen MK, Vainio M, Jalkanen S, Jalkanen M, Mandelin J. Nonclinical Characterization of Bexmarilimab, a Clever-1-Targeting Antibody for Supporting Immune Defense Against Cancers. Mol Cancer Ther. 2022 Jul 5;21(7):1207-1218. doi: 10.1158/1535-7163.MCT-21-0840.
- Virtakoivu R, Rannikko JH, Viitala M, Vaura F, Takeda A, Lonnberg T, Koivunen J, Jaakkola P, Pasanen A, Shetty S, de Jonge MJA, Robbrecht D, Ma YT, Skytta T, Minchom A, Jalkanen S, Karvonen MK, Mandelin J, Bono P, Hollmen M. Systemic Blockade of Clever-1 Elicits Lymphocyte Activation Alongside Checkpoint Molecule Downregulation in Patients with Solid Tumors: Results from a Phase I/II Clinical Trial. Clin Cancer Res. 2021 Aug 1;27(15):4205-4220. doi: 10.1158/1078-0432.CCR-20-4862. Epub 2021 Jun 2.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- FP2CLI001
- 2018-002732-24 (EudraCT Number)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cancer
-
University of Michigan Rogel Cancer CenterRecruitingCancer Liver | Cancer Brain | Cancer Head &Neck | Cancer PelvisUnited States
-
Cellworks Group Inc.RecruitingCancer | Relapsed Cancer | Refractory CancerUnited States
-
UNC Lineberger Comprehensive Cancer CenterHyundai Hope On WheelsRecruitingCancer | Pediatric Cancer | Survivorship | Cancer MetastaticUnited States
-
Vanderbilt-Ingram Cancer CenterNational Institutes of Health (NIH)Active, not recruitingAdvanced Cancer | Relapsed Cancer | Refractory CancerUnited States
-
City of Hope Medical CenterNational Cancer Institute (NCI)CompletedStage III Pancreatic Cancer | Stage IIA Pancreatic Cancer | Stage IIB Pancreatic Cancer | Stage IV Gastric Cancer | Stage IVA Colorectal Cancer | Stage IVA Pancreatic Cancer | Stage IVB Colorectal Cancer | Stage IVB Pancreatic Cancer | Stage IIIA Gastric Cancer | Stage IIIB Gastric Cancer | Stage IIIC Gastric... and other conditionsUnited States
-
MiRXES Pte LtdRecruitingBreast Cancer | Gastric Cancer | Colorectal Cancer | Pancreatic Cancer | Esophageal Cancer | Ovarian Cancer | Prostate Cancer | Thoracic Cancer | Liver CancerSingapore
-
Sidney Kimmel Cancer Center at Thomas Jefferson...CompletedStage I Breast Cancer | Stage I Uterine Corpus Cancer | Stage II Uterine Corpus Cancer | Stage III Uterine Corpus Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage... and other conditionsUnited States
-
Massachusetts General HospitalNational Comprehensive Cancer NetworkCompletedGastric Cancer | Pancreatic Cancer | Esophageal Cancer | Rectal Cancer | Colon Cancer | Hepatobiliary CancerUnited States
-
University of California, San FranciscoBristol-Myers Squibb; PfizerTerminatedStage IIIA Rectal Cancer | Stage IIIB Rectal Cancer | Stage IIIC Rectal Cancer | Metastatic Colorectal Adenocarcinoma | Metastatic Colon Adenocarcinoma | Metastatic Rectal Adenocarcinoma | Stage IIIA Colon Cancer | Stage IIIB Colon Cancer | Stage IIIC Colon Cancer | Stage IV Colon Cancer | Stage IV Rectal... and other conditionsUnited States
-
Johns Hopkins UniversityNational Cancer Institute (NCI); National Institute on Minority Health and...Enrolling by invitationCancer | Advanced Cancer | End Stage Cancer | MalignancyUnited States
Clinical Trials on FP-1305 (bexmarilimab)
-
The University of Texas Health Science Center at...Faron Pharmaceuticals LtdWithdrawnNon-small Cell Lung CancerUnited States
-
Faron Pharmaceuticals LtdRecruitingAcute Myeloid Leukemia | Myelodysplastic Syndromes | Chronic Myelomonocytic Leukemia | Relapsed/Refractory AMLUnited States, Finland
-
FHI 360Ministry of Health, UgandaCompletedCommunity-based Delivery of Integrated Family Planning/HIV Testing and Counseling Services in UgandaHIV Testing and CounselingUganda
-
Faron Pharmaceuticals LtdWithdrawn
-
DualityBio Inc.RecruitingAdvanced Solid TumorUnited States, China, Puerto Rico
-
Immune Targeting Systems LtdCompleted
-
Foresee Pharmaceuticals Co., Ltd.Completed
-
CSL BehringCompletedHemophilia BUnited States, Japan, Israel, Austria, Bulgaria, France, Germany, Italy, Russian Federation, Spain
-
Fervent PharmaceuticalsICON plcCompletedVasomotor Symptoms | MenopauseUnited States
-
Five Prime Therapeutics, Inc.ParexelCompleted